955 related articles for article (PubMed ID: 16712662)
81. NIS and epithelial-mesenchymal transition marker expression of circulating tumor cells for predicting and monitoring the radioactive iodine-131 therapy effect in differentiated thyroid cancers.
Zheng L; Wang G; Guo W; Pan D; Xie L; He S; Luo C; Li H; Ran Y; Wu S; Liu F; Zhang X; Huang D
Mol Biol Rep; 2019 Aug; 46(4):4201-4212. PubMed ID: 31147861
[TBL] [Abstract][Full Text] [Related]
82. Radioactive iodine offers survival improvement in patients with follicular carcinoma of the thyroid.
Podnos YD; Smith D; Wagman LD; Ellenhorn JD
Surgery; 2005 Dec; 138(6):1072-6; discussion 1076-7. PubMed ID: 16360393
[TBL] [Abstract][Full Text] [Related]
83. Differentiated thyroid carcinoma in a juvenile patient.
Khan MU; Nawaz MK; Saadullah M; Syed AA; Hussain R; Azhar R; Shah MA
Clin Nucl Med; 2008 May; 33(5):319-20. PubMed ID: 18431142
[TBL] [Abstract][Full Text] [Related]
84. The comparative effects of gene modulators on thyroid-specific genes and radioiodine uptake.
Tuncel M; Aydin D; Yaman E; Tazebay UH; Güç D; Doğan AL; Taşbasan B; Uğur O
Cancer Biother Radiopharm; 2007 Apr; 22(2):281-8. PubMed ID: 17600477
[TBL] [Abstract][Full Text] [Related]
85. Digitalislike Compounds Restore hNIS Expression and Iodide Uptake Capacity in Anaplastic Thyroid Cancer.
Tesselaar MH; Crezee T; Schuurmans I; Gerrits D; Nagarajah J; Boerman OC; van Engen-van Grunsven I; Smit JWA; Netea-Maier RT; Plantinga TS
J Nucl Med; 2018 May; 59(5):780-786. PubMed ID: 29242405
[TBL] [Abstract][Full Text] [Related]
86. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine.
Jaber T; Waguespack SG; Cabanillas ME; Elbanan M; Vu T; Dadu R; Sherman SI; Amit M; Santos EB; Zafereo M; Busaidy NL
J Clin Endocrinol Metab; 2018 Oct; 103(10):3698-3705. PubMed ID: 30032208
[TBL] [Abstract][Full Text] [Related]
87. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
[TBL] [Abstract][Full Text] [Related]
88. Re-induction of cell differentiation and (131)I uptake in dedifferentiated FTC-133 cell line by TSHR gene transfection.
Feng F; Wang H; Hou S; Fu H
Nucl Med Biol; 2012 Nov; 39(8):1261-5. PubMed ID: 22898315
[TBL] [Abstract][Full Text] [Related]
89. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
90. Estimation of Second Primary Cancer Risk After Treatment with Radioactive Iodine for Differentiated Thyroid Carcinoma.
Corrêa NL; de Sá LV; de Mello RC
Thyroid; 2017 Feb; 27(2):261-270. PubMed ID: 27762670
[TBL] [Abstract][Full Text] [Related]
91. Effects of dose, intervention time, and radionuclide on sodium iodide symporter (NIS)-targeted radionuclide therapy.
Shen DH; Marsee DK; Schaap J; Yang W; Cho JY; Hinkle G; Nagaraja HN; Kloos RT; Barth RF; Jhiang SM
Gene Ther; 2004 Jan; 11(2):161-9. PubMed ID: 14712300
[TBL] [Abstract][Full Text] [Related]
92. Determination of the optimal time for radioiodine therapy in anaplastic thyroid carcinoma using the adenovirus-mediated transfer of sodium iodide symporter gene.
So Y; Lee YJ; Lee WW; Chung JK
Oncol Rep; 2013 Apr; 29(4):1666-70. PubMed ID: 23404348
[TBL] [Abstract][Full Text] [Related]
93. Radiation Dose-rate Reduction Pattern in Well-differentiated Thyroid Cancer Treated with I-131.
Khan SA; Khan MS; Arif M; Durr-e-Sabih ; Rahim MK; Ahmad I
J Coll Physicians Surg Pak; 2015 Jul; 25(7):510-3. PubMed ID: 26208555
[TBL] [Abstract][Full Text] [Related]
94. Reestablishment of in vitro and in vivo iodide uptake by transfection of the human sodium iodide symporter (hNIS) in a hNIS defective human thyroid carcinoma cell line.
Smit JW; Shröder-van der Elst JP; Karperien M; Que I; van der Pluijm G; Goslings B; Romijn JA; van der Heide D
Thyroid; 2000 Nov; 10(11):939-43. PubMed ID: 11128720
[TBL] [Abstract][Full Text] [Related]
95. In vivo sodium iodide symporter gene therapy of prostate cancer.
Spitzweg C; Dietz AB; O'Connor MK; Bergert ER; Tindall DJ; Young CY; Morris JC
Gene Ther; 2001 Oct; 8(20):1524-31. PubMed ID: 11704812
[TBL] [Abstract][Full Text] [Related]
96. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
97. Evaluation of the surgical completeness after total thyroidectomy for differentiated thyroid carcinoma.
Salvatori M; Raffaelli M; Castaldi P; Treglia G; Rufini V; Perotti G; Lombardi CP; Rubello D; Ardito G; Bellantone R
Eur J Surg Oncol; 2007 Jun; 33(5):648-54. PubMed ID: 17433606
[TBL] [Abstract][Full Text] [Related]
98. Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature.
Zhang X; Liu DS; Luan ZS; Zhang F; Liu XH; Zhou W; Zhong SF; Lai H
Clin Transl Oncol; 2018 Jul; 20(7):928-935. PubMed ID: 29119458
[TBL] [Abstract][Full Text] [Related]
99. Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.
Grigsby PW; Reddy RM; Moley JF; Hall BL
Surgery; 2006 Dec; 140(6):1043-7; discussion 1047-9. PubMed ID: 17188155
[TBL] [Abstract][Full Text] [Related]
100. Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells.
Kogai T; Sajid-Crockett S; Newmarch LS; Liu YY; Brent GA
J Endocrinol; 2008 Nov; 199(2):243-52. PubMed ID: 18762555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
